Importantly, in vivo studies demonstrated that treatment with KRB-456 of mice bearing PDXs from pancreatic cancer patients resulted in inhibition of the PDX's P-MEK but not P-ERK levels. The gene discussed is MAP2K7; the disease is pancreatic neoplasm.